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Background
Although the majority of patients with acute myeloid leukemia initially respond to convention-
al chemotherapy, relapse is still the leading cause of death, probably because of the presence of
leukemic stem cells that are insensitive to current therapies. We investigated the antileukemic
activity and mechanism of action of zalypsis, a novel alkaloid of marine origin.
Design and Methods
The activity of zalypsis was studied in four acute myeloid leukemia cell lines and in freshly iso-
lated blasts taken from patients with acute myeloid leukemia before they started therapy.
Zalypsis-induced apoptosis of both malignant and normal cells was measured using flow
cytometry techniques. Gene expression profiling and western blot studies were performed to
assess the mechanism of action of the alkaloid.
Results
Zalypsis showed a very potent antileukemic activity in all the cell lines tested and potentiated
the effect of conventional antileukemic drugs such as cytarabine, fludarabine and daunorubicin.
Interestingly, zalypsis showed remarkable ex vivo potency, including activity against the most
immature blast cells (CD34+ CD38- Lin-) which include leukemic stem cells. Zalypsis-induced
apoptosis was the result of an important deregulation of genes involved in the recognition of
double-strand DNA breaks, such as Fanconi anemia genes and BRCA1, but also genes implicat-
ed in the repair of double-strand DNA breaks, such as RAD51 and RAD54. These gene findings
were confirmed by an increase in several proteins involved in the pathway (pCHK1, pCHK2
and pH2AX). 
Conclusions
The potent and selective antileukemic effect of zalypsis on DNA damage response mechanisms
observed in acute myeloid leukemia cell lines and in patients’ samples provides the rationale
for the investigation of this compound in clinical trials.
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous clon-
al disorder of hematopoietic progenitor cells that lose their
ability to differentiate normally and to respond to normal
regulators of proliferation.1-3 Treatment of AML has tradi-
tionally relied on the combination of the pyrimidine analog
cytarabine (araC) with anthracycline antibiotics such as
daunorubicin, and has not evolved for more than 30
years.1,4 Although the majority of patients initially respond,
relapse is the leading cause of death in AML, probably due,
among other reasons, to the presence of leukemic stem
cells, which are relatively insensitive to current therapies.5,6
The problem of relapse is especially notorious in patients
with complex karyotypes and secondary AML, who have
a dismal prognosis.3,7 Several cytogenetic abnormalities
such as TP53 mutations are particularly frequent in this
subset of patients with a bad prognosis.8-14 In this regard,
the presence of a functional p53 is necessary for the induc-
tion of cell death caused by most antitumoral agents,
whereas a non-functional p53 is clearly associated with the
development of drug resistance.15
One of the sources of drugs which has attracted interest
in recent years is the marine environment.16 The antitumor
activity of many compounds obtained from tunicates and
other sea organisms is being tested in preclinical and clini-
cal studies, and some of them, such as Yondelis®, have
already been approved for the treatment of advanced soft
tissue sarcomas and ovarian cancer.17 Zalypsis (PM00104) is
a new synthetic alkaloid related to jorumycin, renier-
amycins, safracins and saframycins. Zalypsis has demon-
strated significant in vitro and in vivo activity against human
solid and hematologic neoplasms via p53-dependent and
p53-independent mechanisms,18,19 and is currently being
evaluated in early phase clinical trials on solid organ neo-
plasms and multiple myeloma.
In this study we investigated the activity and mechanism
of action of zalypsis in AML cell lines and patients’ samples
with different biological and cytogenetic characteristics.
Design and Methods
Reagents and immunochemicals
Cell culture media, serum and penicillin-streptomycin were
from Invitrogen Corporation (Gaithersburg, MD, USA). Zalypsis
was provided by PharmaMar S.A.U., (Madrid, Spain and
Cambridge, MA, USA). Daunorubicin, cytarabine and fludarabine
were purchased from Sigma-Aldrich (Madrid, Spain). Annexin V-
fluorescein isothiocyanate (FITC) was obtained from BD
Biosciences (San Diego, CA. USA). Z-VAD-FMK was purchased
from Calbiochem (San Diego, CA, USA). Other generic chemicals
were purchased from Sigma-Aldrich, Roche Biochemicals
(Mannheim, Germany), or Merck (Darmstadt, Germany).
The providers of the different monoclonal antibodies employed
in the western blotting analyses were as follows: anti-GADD45B,
anti-p21, anti-MDM2, anti-PUMA, anti-Bcl-2 and anti-Mcl-1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-AIF, anti-
pH2AX; anti-Bax, anti-pCHK1, anti-pCHK2, anti-p53, anti-Bcl-XL,
anti-PARP, anti-caspase-3, anti-caspase-7, anti-caspase-8 and anti-
caspase-9 (Cell Signaling, Boston, MA, USA); anti-cytochrome c
(BD Biosciences); anti-tubulin (Calbiochem, San Diego, USA); and
anti-endo G (Serotec, Raleigh, USA). The horse radish peroxidase-
conjugated secondary antibodies were from Amersham
(Buckinghamshire, UK).
Cell cultures, cell proliferation, cell cycle, 
and apoptosis analyses and western blotting 
and subcellular fractionation procedures
The source and the culture conditions of the AML cell lines as
well as the detailed methodology for analyzing proliferation of
AML cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl -
tetrazolium bromide (MTT) assay, cell cycle profiles, cytometric
evaluation of apoptosis in AML cell lines using annexin-V-FITC,
mitochondrial membrane potential (ΔΨm), subcellular fractionation
and western blotting have been described previously.20
For combination experiments, we used suboptimal doses of
zalypsis, daunorubicin, cytarabine, fludarabine and bortezomib
for 24 and 48 h, and analyzed the cytotoxicity of the combination
by MTT absorbance assays as previously described.21,22
Ex vivo experiments in freshly isolated acute 
myeloid leukemia cells
The use of clinical samples for investigation was approved by
the Ethical Committee of the University Hospital of Salamanca.
The cytometric analyses of apoptosis have been described else-
where.20 Briefly, bone marrow cells were obtained from ten
patients with AML at diagnosis before any treatment. The biolog-
ical characteristics of these patients are summarized in Table 1.
Bone marrow cells (1×106) were incubated in six-well plates with
zalypsis (10 nM) or in the absence of drug (control) for 18 h at 37
ºC in a humidified atmosphere in the presence of 5% CO2-95%
air. Using quadruple staining, we were able to identify the blast
cell population (CD34-/+, CD33-/+, CD45dim)23 and the population of
the most immature blasts in which leukemic stem cells are found
(CD34+, CD38-, Lin-), and accurately quantify the number of apop-
totic cells in each cell population.24-26 In addition, the toxicity to
normal hematopoietic progenitor cells (CD34+) was analyzed in
bone marrow samples from four non-leukemic patients. In all
cases, the percentage of apoptotic events was corrected according
to the proportion of apoptotic cells in the control (untreated) cells.
The monoclonal antibodies used for these experiments were: anti-
CD33-PE; anti-CD45-PerCP; anti-CD34-APC; anti-CD64-PE; anti-
CD19-PerCP-Cy5.5; anti-CD45-AmCyan and anti-CD38-Alexa-
Fluor-700 (BD Biosciences, San Diego, CA, USA). 
Microarray RNA analyses
HEL and HL60 cells were treated with zalypsis (10 nM) for 16 h
in order to obtain 20% apoptosis, as assessed by annexin-V stain-
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Table 1. Baseline characteristics of the AML patients’ samples.
Cytogenetics FLT3 NPM1 CD34
mutation mutation expression
AML 1* No mitosis WT WT +
AML 2 Normal NE NE -
AML 3 NE NE NE +
AML 4 46,XY [12]/46,XY,+8 [5]/ WT WT +
48,idem,+mar [4]
AML 5 Normal ITD Mut -
AML 6 46,XY [8]/47,XY,+8 [5]/ WT WT +
47,idem,-14,+mar [3]
AML 7 45,XX, -22 [17] WT WT +
AML 8 † 46,XX [5]/47,XX,+11 [11] WT WT +
AML 9 46,XX [4]/46,XX,-10,-13,+2mar [4] WT NE +
AML 10 Normal ITD WT -
FLT3: fms-like tyrosine kinase 3; ITD: internal tamdem duplication; NPM1: nucleophosmin;
NE: not evaluated; Mut: mutated; +: positive; -: negative. *FISH studies demonstrated a loss
of 5q in 84% of cells; †molecular studies demonstrated a JAK2 mutation.
ing.21 At this time point, the total RNA was extracted using Trizol
reagent (Life Technologies, MD, USA) and purified with an
RNAeasy Mini Kit (Qiagen, CA, USA). HEL and HL60 cells cul-
tured in the same conditions in the absence of drug were used as
controls. RNA integrity was verified with the Agilent 2100
Bioanalyzer (Agilent, CA, USA). Double-strand cDNA and
biotinylated cRNA were synthesized with T7-polyT primer and
the BioArray RNA labeling kit (Enzo, NY, USA), respectively. The
labeled RNA was then fragmented and hybridized to HG-U133
Plus 2.0 oligonucleotide arrays (Affymetrix, CA, USA), which
were scanned in a Gene Array Scanner and analyzed using DNA-
Chip Analyzer software (DChip) and Ingenuity Pathway Analysis
(Ingenuity Systems, California, USA). Greater than two-fold
changes in gene expression were considered significant.
Real-time quantitative polymerase chain reaction
The results obtained from microarrays were confirmed by real-
time quantitative polymerase chain reaction (PCR). The sequences
of the primers used are shown in Online Supplementary Table S1.
The reactions were performed using iQTM SYBR Green Supermix
(Bio-Rad Laboratories, Madrid). A standard curve was made using
serial dilutions (20 ng, 2 ng and 0.2 ng) of control cDNA. The PCR
conditions were: (step 1) 95ºC for 10 min; (step 2 , x40) 95ºC for
15 s and 58ºC for 1 min; (step 3) 95ºC for 1 min; (step 4) 65ºC for
1 min; (step 5, x60) 65ºC for 10 s; (step 6) 4ºC. Quantification was
based on increased fluorescence, which was measured and record-
ed using Bio-Rad iQ5 software; the results were normalized to
those of the reference gene, GAPDH.
Fluorescent microscopy
Cells were collected, washed with phosphate-buffered saline,
fixed with 4% formaldehyde (1 h) and then permeabilized with
0.1% Triton X-100 (3 s). After this, the cells were washed again
with phosphate-buffered saline and incubated with blocking solu-
tion (10% bovine serum albumin in phosphate-buffered saline for
30 s). After washing with phosphate-buffered saline, the cells
were incubated with rabbit antibody against pH2AX (Ser139)
(Cell Signaling Technology, Danvers, MA, USA) overnight at 4ºC
and then with AlexaFluor488 goat anti-rabbit antibody
(Invitrogen, Eugene, OR, USA) for 30 s at room temperature. Cells
were incubated with DAPI (0.5 mg/mL), placed onto slides by
cytospin and then mounted using Vectashield mounting medium
(Vector Laboratories, Burlingame, CA, USA). A Leica confocal
microscope was used to obtain confocal images. At least six
images were taken for each condition, and the percentage of cells
with positive pH2AX nuclear foci with respect to the total number
of cells (total DAPI-stained nuclei excluding apoptotic cells) was
calculated using Scion Image software. 
Statistics
Statistical significance was calculated by Student’s t-test, the
Mann-Whitney U or Wilcoxon signed rank test as appropriate,
with Prism software (GraphPad). All P values less than 0.05 are
considered statistically significant and are referred to as such in the
text. Unless otherwise specified, all studies for which data are pre-
sented are representative of at least two similar studies.
Results
Zalypsis displays potent antileukemic activity 
and potentiates the effects of conventional
antileukemic agents
To test the antiproliferative/cytotoxic effect of zalypsis
against AML cells, four cell lines were treated with
increasing concentrations of the compound (0.1-10 nM)
for 24 and 48 h, and the viability of the cells was analyzed
by an MTT assay (Figure 1A). Zalypsis showed a very
potent antileukemic activity in the four AML cell lines
tested, with IC50 values at 48 h below 1 nM. When com-
pared with the in vitro activity of conventional
antileukemic agents, the potency of zalypsis was found to
be 10 to 100 times higher than that of cytarabine,
daunorubicin or fludarabine (data not shown). 
To determine whether zalypsis could increase the activ-
ity of standard-of-care drugs for AML, two different cell
lines, HEL and HL60 cells originally derived from patients
with French-American-British M2 AML and erythroid
leukemia, respectively, were treated with several combi-
nations of zalypsis and some conventional antileukemic
agents (cytarabine, daunorubicin, fludarabine) and the
novel drug bortezomib. Zalypsis increased the effect of all
these anti-AML drugs, with the most potent combination
in both cell lines being the one that included the anthracy-
cline, daunorubicin. Zalypsis slightly increased the effect
of cytarabine and fludarabine, whereas only a modest
effect was observed in combination with bortezomib
(Figure 1B). The greater potentiation in the case of HL-60
cells was observed at earlier time points (24 h), probably
due to the higher potency of zalypsis in this cell line,
whereas in HEL cells, 48 h were required for a similar
activity.
Zalypsis targets both mature and immature blast cells
We next analyzed the activity of zalypsis in freshly iso-
lated blast cells from ten AML patients by using multipara-
metric flow cytometry which allows the identification of
blast cells, and, more interestingly, discrimination of the
more mature leukemic cell populations (CD34-/+, CD33-/+,
CD45dim) from the most immature population (CD34+,
CD38-, Lin-).6,27 At concentrations that can be clinically
achieved in the plasma of treated patients, zalypsis
induced significant cell death of the blast population in all
cases analyzed (Figure 1C) which, interestingly, included
patients with bad cytogenetic prognosis based on kary-
otypic abnormalities or molecular mutations (Table 1). In
four of these patients we were also able to analyze the
efficacy of zalypsis in the most immature blast population,
which is thought to include the leukemic stem cells; in all
cases, this population was also sensitive to zalypsis (Figure
1C and D). Finally, we studied the activity of this drug in
non-tumoral CD34+ bone marrow progenitors obtained
from four non-AML samples. In these samples, the CD34+
progenitors were preserved after treatment with zalypsis
(Figure 1C), in particular, the CD34+CD38-Lin- population
which represents the compartment of the non-lineage-
committed hematopoietic progenitors (data not shown).
These findings suggest that although zalypsis may target
the leukemic stem cell compartment, the cytopenias
caused by the treatment would be reversible, since the
normal immature hematopoietic precursor cells are pre-
served.
Zalypsis induces apoptosis in acute myeloid 
leukemia cells
To assess whether the decrease of MTT uptake induced
by zalypsis was due to cell cycle blockade, an increase in
cytotoxicity, or both, HEL and HL60 cells were treated
with zalypsis (10 nM) for different periods, and, after-
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wards, changes in cell cycle profiles and induction of
apoptosis were analyzed by flow cytometry. Propidium
iodide staining did not show significant changes in the cell
cycle phases (data not shown). By contrast, a significant,
time-dependent induction of annexin V-positive cells was
observed after treatment with zalypsis (Figure 2A) and,
accordingly, zalypsis induced DNA laddering in both HL-
60 and HEL cell lines (Figure 2B). We next evaluated the
biochemical parameters that are affected by apoptotic cell
death. Zalypsis provoked PARP, caspase-3, caspase-7, cas-
pase-8 and caspase-9 cleavage, with generation of active
cleaved fragments in both cell lines (Figure 2C). This indi-
cates that zalypsis activates both the intrinsic and the
extrinsic apoptotic pathways.28 Interestingly, and concor-
dant with the results of the annexin V studies, the cleavage
of these proteins occurred earlier in HL60 cells than in HEL
ones: thus, while the processing of PARP, effector caspases
3 and 7, and caspase 8 required 24 h of treatment with
zalypsis in the HEL cell line, it was already observed at 12
h in HL60 cells. Cleavage of caspase 9 was the first bio-
chemical process observed, after 6 h in HL60 cells and
after 12 h in HEL ones.
Zalypsis deregulates mitochondrial permeability 
in acute myeloid leukemia cells
As cleavage of caspase 9 is a very early event in zalyp-
sis-induced apoptosis, and this change indicates activation
of the intrinsic pathway of apoptosis, we next studied the
effect of zalypsis on mitochondria, which are critically
involved in the triggering of apoptotic cell death through
this pathway. For this purpose we first used DioC6(3) dye
to explore whether zalypsis was able to induce changes in
the mitochondrial membrane potential (ΔΨm), a situation
that results in an increase in the mithocondrial outer mem-
brane permeability.29 A decrease in ΔΨm after treatment
with zalypsis was observed in both cell lines, with this
change occurring earlier in HL60 cells (observed after 6 h)
than in HEL cells (24 h) (Figure 2D).
Bcl-2 family members act as important regulators of
mitochondrial outer membrane permeability. Western
E. Colado et al.
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Figure 1. Effect of zalypsis on the proliferation of acute myeloid
leukemia (AML) cells. (A) MTT uptake of AML cell lines incubated
with different doses of zalypsis. Cells were plated at identical densi-
ties in 96-well dishes and zalypsis was added at the indicated con-
centrations (X axis). Cell viability after 24 and 48 h was analyzed by
MTT assay. MTT metabolization (Y axis) is referred to the average
proliferation values of control untreated samples under identical cul-
ture conditions (100%). Data are represented as the mean of quad-
ruplicates of an experiment that was repeated at least twice. (B)
Zalypsis was combined with suboptimal doses of antileukemic
drugs such as daunorubicin (Dauno), cytarabine (Ara-C), fludarabine
(Fluda) and bortezomib (Bort) and the cytotoxic effect was analyzed
by MTT assays. 
(C) Zalypsis has antileukemic activity against both mature and inmature AML cells. Freshly isolated bone marrow cells obtained from ten
AML patients were plated in six-well plates, and treated ex vivo with zalypsis (10 nM) or without drug (control) for 18 h. After the incubation
period, cells were stained with anti-annexin V-FITC and a combination of monoclonal antibodies which allowed the discrimination of blast
cells (BC). In samples from four AML patients we separately analyzed apoptosis induction in the immature blast cell compartment or
leukemic stem cells (LSC) (CD34+, CD38-, Lin-) and compared it to that of the same population obtained from four patients with non-tumoral
CD34+ bone marrow progenitor cells (HSC). The number of annexin V-positive events in this population was measured and normalized to
the viable cell fraction in the control, untreated cells, as described in the Design and Methods section. (D) Representative example of the
apoptosis study on the immature blast cell compartment. CD34+ cells were gated. The first graph allows the identification of the immature
populations with the two monoclonal antibodies CD34 and CD38; the second plot shows the quantification of apoptosis induction (by annex-
in-V staining) in each compartment; normal HSC are shown as blue dots and LSC are shown as red dots.
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blot analyses indicated that zalypsis down-regulated Bcl-2
in both cell lines, as shown in Figure 2E. Other Bcl-2 fam-
ily members studied, such as MCL-1 and BLC-XL, were
processed only in HL60 cells after treatment with zalypsis,
and their level was stable or even increased in the HEL cell
line, probably acting as paradoxical survival signals in
order to counterbalance the cytotoxic activity of zalypsis.
Zalypsis induces cell death through caspase-dependent
and caspase-independent pathways
The increase in mitochondrial outer membrane perme-
ability also favors the release of mediators of the intrinsic
pathway of apoptosis such as cytochrome C which,
together with APAF-1 and caspase 9, forms the apopto-
some. Subcellular fractionation of HEL and HL60 cells
treated for 18 h with zalypsis showed that this drug
caused a translocation of cytochrome C from the mito-
chondrial to the cytosolic fraction after treatment (Figure
3A), confirming the activation of the intrinsic pathway of
apoptosis. To further investigate the importance of caspas-
es in the anti-leukemic action of zalypsis, the ability of the
pan-caspase inhibitor Z-VAD-FMK to rescue cells from
zalypsis-induced cell death was evaluated.30 Cells were
preincubated for 60 min with Z-VAD-FMK, then zalypsis
was added, and the incubation continued for 24 h. As
shown in Figure 3B, preincubation with the pan-caspase
inhibitor did not abrogate cell death in the HEL cell line
and only a mild effect was observed in HL60 cells. In line
with these results, AIF, one of the proteins involved in cas-
pase-independent apoptosis, was also released into the
cytosol (Figure 3A) after treatment with zalypsis. These
results indicate that both caspase-dependent and caspase-
independent mechanisms are involved in zalypsis-induced
apoptosis. 
Zalypsis induces a profound gene deregulation
To further investigate the mechanism of action of zalyp-
sis, we analyzed treatment-induced changes in the gene
expression profile of two AML cell lines. In order to ana-
lyze changes specifically associated with the effect of
zalypsis and not with late induction of apoptosis, we col-
lected cells at the very beginning of apoptosis; for this pur-
pose, HEL and HL60 cells were treated with zalypsis (10
nM) for 16 h in order to obtain 20% apoptosis, as assessed
by annexin-V staining. Based on a fold-change of two or
more compared to the untreated cell line, a total of 1685
genes were found to be deregulated in HEL cells after
treatment with zalypsis, whereas in the HL60 cell line a
more profound deregulation of gene expression was
observed, with 5576 altered genes. Most of these genes
were down-regulated after treatment with the drug. The
most significantly deregulated functional categories were
cell cycle (568 and 606 genes, respectively), DNA replica-
tion, recombination and repair (333 and 424 genes, respec-
Zalypsis activity in AML
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Figure 2. Zalypsis causes apoptotic cell
death in acute myeloid leukemia cell
lines. (A) Time-course of the effect of
zalypsis on HEL and HL60 cells. Cells
were plated in six-well plates, treated for
different times with zalypsis (10 nM).
Cells were stained with annexin V-FITC
and propidium iodide (B) Zalypsis pro-
vokes internucleosomal DNA fragmenta-
tion, HEL and HL60 cells were treated
with zalypsis for the indicated times and
DNA was isolated and analyzed by
agarose gel electrophoresis. (C) HEL and
HL60 cells were treated with zalypsis (10
nM) for the indicated times, and the
expression of PARP, caspase-3, caspase
7, caspase-8 and caspase-9 proteins ana-
lyzed by western blotting. Tubulin was
used as a loading control. (D) In order to
assess the loss of ΔΨm, HEL and HL60
cells were treated with zalypsis (10 nM)
for the indicated times, propidium iodide-
negative cells were gated and the expres-
sion of DiOC6(3) was analyzed by flow
cytometry. The percentage of DiOC6(3)low
cells is indicated. (E) HEL and HL60 cells
were treated with zalypsis (10 nM) for the
indicated times, and cell extracts were
used for western blotting with anti-Bcl-2,
anti-Bcl-X or anti-MCL-1 antibodies.
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tively), RNA post-transcriptional modification (96 and 173
genes, respectively) and cell death (823 and 967 genes,
respectively). 
Interestingly, 934 genes were deregulated in both cell
lines (Figure 4A). When we focused on this group of
genes, an important number of DNA damage response
genes were found to be deregulated (Table 2). The dereg-
ulated genes also included some implicated in the recog-
nition of double-strand breaks, such as Fanconi anemia
genes (including BRCA2) and BRCA1, and in the repair of
double-strand breaks, such as RAD51 and RAD54. A pos-
sible mechanism of action of zalypsis is, therefore, the
induction of DNA double-strand breaks. The MRN com-
plex is composed of Mre11, Rad50 and Nbs1; it acts as a
sensor of double-stand breaks and recruits the ATM
kinase to sites of broken DNA. This complex therefore
plays a key role in the immediate early response to DNA
damage.31-33 Under these circumstances, ATM is activated
and phosphorylates substrates such as histone H2AX and
CHK2.34,35 These results were confirmed using western
blotting, since treatment of HEL and HL60 cells with
zalypsis induced histone H2AX and CHK2 phosphoryla-
tion (Figure 4B). In fact, using immunocytochemistry we
observed a time-dependent intranuclear localization of
pH2AX in the form of nuclear foci after treatment with
daunorubicin and, even more markedly, with daunoru-
bicin plus zalypsis (Figure 4C). Of note, genes involved in
mismatch repair, such as MLH1 and MSH6, were also
highly deregulated. In addition, there was a significant
increase in GADD45B levels after treatment with zalyp-
sis, reinforcing the belief that the DNA damage pathway
is an important mechanism for the cytotoxic effect
induced by this drug (Figure 4B). 
To further confirm the effects of zalypsis, changes in the
RNA expression of genes found to be deregulated in the
gene expression profiling experiments were also analyzed
by quantitative PCR. We focused on genes related to DNA
damage response as this was the most deregulated path-
way. As shown in Online Supplementary Figure S1, we con-
firmed that in both HEL and HL60 cells exposed to the
drug there was up-regulation of GADD45B and down-reg-
ulation of other genes involved in DNA damage detection
and repair pathways such as Fanconi anemia genes
(BRCA2, FANCG, FANCL), BRCA1, RAD51, RAD54,
CHEK2, ATR, MSH6 and MLH1.
In previous studies of multiple myeloma performed by
our group,18 we had observed that although zalypsis was
able to induce cell death in all myeloma cell lines, those
cells with low basal levels of p53 by western-blot (indicat-
ing wild-type p53) were more sensitive to the drug. This
situation was also confirmed in AML as all cell lines were
extremely sensitive to zalypsis irrespective of their p53
status. In fact, western blot studies showed that some of
them displayed high basal levels of this protein, corre-
sponding to mutated p53 (HEL and MV4-11),36 whereas
p53 expression in the two other cell lines was low (Figure
4D). Interestingly, the more sensitive cell line (HL-60) dis-
played the lowest levels of p53, whereas the less sensitive
line (HEL) had high levels of this protein. In HL-60 cells,
exposure to zalypsis stabilized or slightly increased the
levels of this protein (Figure 4E). In contrast, the HEL cell
line, which has high basal levels of p53, showed no
increase in the expression of the protein. The increase in
p53 levels in HL60 cells is likely due to stabilization of the
protein, as no evident changes in mRNA levels were
observed in the microarray data analysis. Interestingly, 60
genes in the p53 canonical pathway were deregulated in
the HL60 cell line, whereas only 15 genes were deregulat-
ed in the HEL cell line.
Discussion
Nearly 80% of patients with AML achieve complete
remission with induction chemotherapy. However, a high
proportion relapse and eventually die of their disease.1,2
Recent studies have shown that zalypsis may represent a
valuable novel anticancer therapy, with strong preclinical
antineoplastic efficacy and preliminary evidence of activi-
ty and a good safety profile in phase I clinical studies. In
the present study, this compound was found to have a
strong antileukemic activity in cell lines as well as in fresh
leukemic cells from AML patients. Furthermore, zalypsis
potentiated the effect of drugs conventionally used in
AML treatment, supporting the future development of
clinical trials using this drug in combination with daunoru-
bicin or cytarabine among others.
Any successful therapeutic strategy in AML patients
should target not only the mature blast cells, but also the
leukemic stem cell compartment that is responsible for the
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Figure 3. Zalypsis causes cell death through caspase-inde-
pendent mechanisms. (A) HL60 and HEL cells were treat-
ed for the indicated times with zalypsis (10 nM), and the
subcellular distribution of AIF, endonuclease G and
cytochrome C in mitochondrial and cytosolic fractions was
analyzed by western blotting. (B) Effect of the pancaspase
inhibitor, Z-VAD-FMK, on zalypsis-induced cell death. HEL
and HL60 cells were plated and pre-treated, where indicat-
ed, with Z-VAD-FMK (20 mM) for 60 min. Zalypsis (10 nM)
was added to the samples, and the experiment continued
for 24 h. Flow cytometry was carried out as described in
the Design and Methods section. 
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eventual recurrence of the disease. Moreover it is also
important to spare normal hematopoietic stem cells, oth-
erwise severe toxicities could develop, especially at a
hematologic level. To address these issues, we performed
multiparametric flow cytometry experiments in both
malignant and normal cells. Zalypsis showed strong
antileukemic activity in all the studied AML samples,
including CD34+CD38- blast cells which had a similar sen-
sitivity to zalypsis as that of the more mature blast cell
populations. These observations suggest that zalypsis tar-
gets not only the mature but also the immature blast cell
populations, in which leukemic stem cells are thought to
be found. Interestingly, normal hematopoietic stem cells
were almost unaffected under the same conditions, which
indicates that hematologic toxicity would be reversible,
due to the specific action of zalypsis on the leukemic cells. 
The mechanism of action of zalypsis in AML was found
to be multifactorial, and involved a strong apoptotic
response. The apoptosis was detected by both
annexin/propidium iodide staining and DNA laddering
and indirectly by the loss of mithocondrial membrane
potential observed in AML cells. Apoptosis was caspase-
dependent as cleavage of pro-caspases 8, 9 and 3 as well as
PARP was detected, but caspase-independent pathways
such as the release of AIF from mitochondria could also
play a role in zalypsis-induced cell death.
Microarray data interpretation led to the identification
of DNA damage as a potential important mechanism of
action of zalypsis. Gene expression profiling identified
several genes implicated in double-strand break repair and
BRCA1 pathways, Fanconi anemia genes [FANCG,
FANCL, FANCF, BRCA2 (FANCD2), ATR, RAD51,
RAD54L, BRCA1, and BARD1] whose levels were down-
regulated, in addition to other genes also implicated in
DNA mismatch detection and repair such as MSH6 and
MLH1. Western blotting studies confirmed this mecha-
nism as zalypsis up-regulated the levels of pH2AX, a sur-
rogate marker of double-strand breaks as well as pCHK2,
both substrates of ATM. The levels of GADD45B, another
marker of DNA damage, were also higher. A large number
of genes implicated in fundamental cell processes such as
transcription or DNA replication were also deregulated,
indicating that zalypsis provokes DNA damage. DNA
damage and error-prone repair mechanisms, causing
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Figure 4. Zalypsis stimulates a DNA
damage response through the induc-
tion of double-strand breaks. (A) Venn
diagram depicting the overlap of
deregulated genes in HEL and HL60
cells after zalypsis treatment. (B) HEL
and HL60 cells were treated with
zalypsis 10 nM for the indicated time
points, cell protein extracts were
obtained from each condition and the
levels of pH2AX, pCHK1 and pCHK2
and GADD45B were analyzed by west-
ern blotting. (C) Fluorescent
microscopy of pH2AX in HEL and
HL60. Cells were treated with 500 nM
daunorubicin (D) or 500 nM daunoru-
bicin plus 10 nM zalypsis (D+Z) for 3
or 6 h. The percentage of cells with
pH2AX nuclear foci was calculated as
described in the Design and Methods
section. The number of cells with
pH2AX nuclear foci in the absence of
drug was not significantly different
(data not shown). The figure shows, for
each condition, representative images
for DAPI and pH2AX stain and
merged. A representative example of
a cell with pH2AX nuclear foci is indi-
cated with an arrow. Statistical differ-
ences with respect to daunorubicin
treatment are shown as ***P<0.001
and **P<0.01 (Student’s t-test; n=6).
Scale bar = 10 mM. (D) Western blot
showing the basal protein levels of
p53 protein in the four AML cell lines
tested. (E) HEL and HL60 cells were
treated with zalypsis 10 nM for the
indicated time points, cell protein
extracts were obtained from each con-
dition and p53 and p53-dependent
proteins levels were assessed at the
same times. Equal loading was con-
firmed with an anti-tubulin antibody.
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genomic instability, have been implicated in leukemia37-39
and can, therefore, be targeted by drugs inducing addition-
al DNA damage or inhibiting DNA repair pathways.40
Importantly, one of the principal routes involved in the
DNA damage response is the p53 pathway. In cells with
high p53 basal levels and, therefore, non-functional p53,
zalypsis was still able to trigger the DNA damage
response, as indicated by its action on pH2AX and
pCHK2. Consequently, it seems that p53-independent
routes can be activated by zalypsis in AML. Taken togeth-
er, these findings suggest that zalypsis provokes a DNA
damage response, probably double strand breaks in the
DNA, and this may be the leading mechanism of action of
this drug. 
In conclusion, the potent and specific activity of zalypsis
in mature and immature AML blast cells, through the
induction of DNA damage, supports the investigation of
this novel compound in the treatment of this disease in ad
hoc clinical trials, alone or in combination with other
agents. 
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Table 2. Genes involved in the DNA damage pathway deregulated by zalypsis in HEL and HL60 cell lines.
Probe set                       Gene name            HEL fold change           HL60 fold change               Comments
207574_s_at                         GADD45B                           39.10                                     5.08                                growth arrest and DNA-damage-inducible, beta
1565716_at                                 FUS                                  6.52                                      2.53                                fusion (involved in t(12;16) in malignant liposarcoma)
203564_at                                FANCG                              -2.22                                     -5.75                               Fanconi anemia, complementation group G
202520_s_at                             MLH1                               -2.45                                     -4.68                               mutL homolog
201663_s_at                             SMC4                                -2.95                                     -5.37                               structural maintenance of chromosomes 4
201423_s_at                            CUL4A                               -3.39                                     -8.22                               cullin 4A
210416_s_at                            CHEK2                              -3.50                                     -5.39                               CHK2 checkpoint homolog (S. pombe)
218397_at                                 FANCL                               -3.77                                     -5.32                               Fanconi anemia, complementatio group L
209849_at_at                           RAD51                               -3.93                                     -3.45                               RAD51Homolog(S. cerevisiae)
204531_s_at                            BRCA1                              -4.05                                     -4.01                               breast cancer 1, early onset
204558_at                                RAD54L                              -4.35                                    -14.99                              RAD54-like (S. cerevisiae)
208368_s_at                            BRCA2                              -6.45                                    -24.51                              breast cancer 2, early onset
209259_s_at                             SMC3                                -7.52                                    -10.19                              structural maintenance of chromosomes 3
205345_at                                 BARD1                              -7.80                                     -4.54                               BRCA1 associated RING domain 1
201202_at                                  PCNA                              -10.89                                    -4.50                               proliferating cell nuclear antigen
209902_at                  ATR (includes EG:545)               -12.55                                   -19.72                              ataxia telangiectasia and Rad3 related
218689_at                                 FANCF                             -14.12                                    -6.23                               Fanconi anemia, complementation group F
202911_at                                  MSH6                              -21.99                                   -10.44                              mutS homolog
212997_s_at                              TLK2                              -101.25                                  -15.53                              tousled-like kinase 2
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